Therefore we ran an additional experiment, treating mice ip with 500 mg/kg TUDCA every three days, a regimen previously shown to attenuate amyloid-β pathology and reduce neuroinflammation and synaptic loss in the APP/PS1 mouse model of AD [22]. Here, APP is linked to Alzheimer disease.